MedPath

Optical Coherence Tomography for Intracranial Atherosclerotic Stenosis

Recruiting
Conditions
Intracranial Atherosclerosis
Optical Coherence Tomography
Plaque, Atherosclerotic
Artery Stenosis
Ischemic Stroke
Interventions
Procedure: Percutaneous transluminal angioplasty and stenting
Diagnostic Test: Optical Coherence Tomography
Registration Number
NCT05550077
Lead Sponsor
jiaoliqun
Brief Summary

To evaluate the clinical significance of optical coherence tomography (OCT) in interventional treatment of intracranial atherosclerotic stenosis (ICAS).

Detailed Description

Stroke was the second leading cause of death worldwide and the leading cause of death in China in 2017. ICAS accounted for 10% to 15% of ischemic stroke in Western countries, and as much as 46.6%in Asia in 2009.

For patients with ICAS, the risk of stroke is highly related to the histopathology of atheromatous plaques. Therefore, characterizing the morphology and composition of plaques in ICAS may help to predict the risk of stroke occurrence and allow the adoption of preventive or therapeutic management to prevent such life-threatening events. OCT, with a resolution of 10μm, may provide more reliable information in characterizing atheromatous plagues.

This study aims to get a better insight into the value of OCT in evaluating the vessel wall structure and therefore guiding the interventional therapy of ICAS. In addition, the clinical and biological information will be included to achieve correlation analysis so as to get biomarkers subject to various plaque characteristics.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
400
Inclusion Criteria
  • Symptomatic ICAS. Participants with ICAS with a transient ischaemic attack (TIA) or stroke attributable to the territory of the stenotic artery were defined as symptomatic. A TIA was defined as a transient episode of neurological dysfunction (focal weakness or language disturbance, transient monocular blindness, or required assistance in walking) caused by focal brain or retinal ischaemia that lasted for at least 10 minutes but resolved within 24 hours
  • Stenotic degree ≥ 50%, measured by digital subtraction angiography
  • The stenosis must located in at least one major intracranial artery (internal carotid artery, vertebral artery, middle cerebral artery, or basilar artery)
Exclusion Criteria
  • Arteriovenous Malformation
  • Aneurysm

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Non-Optical Coherence Tomography (N-OCT)Percutaneous transluminal angioplasty and stentingClassical imaging evaluation such as TCCD and High resolution-MRI will be performed, followed by standard percutaneous transluminal angioplasty and stenting.
Optical Coherence Tomography (OCT)Optical Coherence TomographyOCT and other classical imaging evaluation such as Transcranial Color Doppler (TCCD) and High resolution-MRI will be performed. The tailored treatment (such as anti-thrombotic management, post-dilation, et al) will be considered when specific plaque characteristics (including but not limited to in situ thrombus formation, macrocacilfication, et al), were observed under OCT.
Optical Coherence Tomography (OCT)Percutaneous transluminal angioplasty and stentingOCT and other classical imaging evaluation such as Transcranial Color Doppler (TCCD) and High resolution-MRI will be performed. The tailored treatment (such as anti-thrombotic management, post-dilation, et al) will be considered when specific plaque characteristics (including but not limited to in situ thrombus formation, macrocacilfication, et al), were observed under OCT.
Primary Outcome Measures
NameTimeMethod
Safety outcomes: short-term death or stroke30 days after enrollment

We defined 'short-term' as the periprocedural period, or mean follow-up time less than or equal to three months after enrollment. Stroke was identified in the vascular territory of the stenosed vessel, either ischaemic or haemorrhagic. We defined death or stroke as a composite of death of any cause or non-fatal stroke of any type in any territory.

Secondary Outcome Measures
NameTimeMethod
Death1 year after enrollment

(long term; more than three months)

Restenosis1 year after enrollment

(≥ 50%) of the involved vessel documented by conventional cerebral angiography

Ipsilateral stroke1 year after enrollment

(same territory as the index stenosis)

Type of recurrent event1 year after enrollment

(TIA, ischaemic stroke, haemorrhagic stroke)

Death or stroke1 year after enrollment

(long term; more than three months)

Dependency1 year after enrollment

Modified Rankin Scale or equivalent

Trial Locations

Locations (1)

Xuanwu Hospital, Capital Medical University

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath